Kazia Therapeutics investor briefing.
For the Kazia shareholders who could not take part in today's zoom webinar, these are my highlights (and should not be taken as financial advice).
Dr James Garner mentioned that commencing 2021, he will strive to have quarterly paxalisib trial data read outs for the next 2 years. IMO that could have something to do with Kazia's paxalisib being granted Fast Track Designation by FDA, and their registration requirement to submit progressive GBM AGILE data efficacy results and consultations before the final FDA approval.
He mentioned the potential of a paxalisib marketing partner any time between 2 to 24 months.
He answered a question and mentioned something to the effect of: At present there are no competitors to paxalisib in the Global pipeline. PI3K is switched on in 90% of Glioblastoma patients, and paxalisib crosses the blood brain barrier.
Cantrixil needs partnering for it to move forward to the next phase.
View the webinar on the Kazia website when available.
Regards..
Kazia Therapeutics investor briefing, page-5
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)